← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › IMMUNE SERA AND IMMUNOGLOBULINS › IMMUNOGLOBULINS › Antiviral monoclonal antibodies
ansuvimab
J06BD04
Forms & Strengths
- Injection: 100 mg/mL
- Single-dose vial
Adult Dosing
- 8mg/kg IV on Day 1, 4mg/kg IV on Days 4, 8, 13, and 18
- Dosing may vary based on treatment protocol
Pediatric Dosing
- Pediatric dosing not established
- Should be used with caution
Indications
- Treatment of Zaire ebolavirus infection
- Treatment of other filovirus infections
Mechanism of Action
- Monoclonal antibody against Ebola virus glycoprotein
- Blocks virus entry into host cells
Contraindications
- Hypersensitivity to ansuvimab or its components
Adverse Reactions
- Infusion-related reactions
- Headache
- Fatigue
Drug Interactions
- None reported
- Caution with live vaccines
Curated Content: Needs Vetting Before Put to Clinical Use